ClinicalTrials.gg
Active, not recruitingNCT04332367Updated Nov 6, 2026

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

A Phase 2 interventional study of Carboplatin and Paclitaxel in Non-small Cell Lung Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Abramson Cancer Center at Penn Medicine · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Updated Nov 6, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 40 under way, 12 of them phase 3. Carboplatin · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
123rd of 251
59 · median 55
Started
2020
with 9 others
Phase 2
149 of 272
11 open now
Primary completion
2026-10
later than 14 of 39 live
Registered
234th of 272
by date

Among the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, this one is the 123rd largest by planned enrollment of the 251 interventional ones that give a count, is one of 10 that started in 2020, is one of 149 in phase 2, reaches primary completion later than 14 of the 39 other live ones, and was the 234th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
  • Prior exposure to 4-6 cycles of Pem/Carbo/Pembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.
  • PS 0-1

Exclusion criteria

Exclusion Criteria:

  • Presence of a driver mutation that is susceptible to targeted therapy
  • Other active invasive requiring ongoing therapy
  • Grade 2 or higher sensory neuropathy
  • Evidence of untreated
  • History of bleeding diatheses or recent, antecedent hemoptysis (> 1/2 teaspoon in prior 2 months)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (estimated)

Study arms

  • Experimental
    Carboplatin, Taxane And Ramucirumab

    Carboplatin AUC 5 IV every 3 wks, Paclitaxel 80 mg/m2 IV days 1 and 8 every 3 weeks, and Ramucirumab 10 mg/kg IV every 3 weeks

    Drug: Carboplatin · Drug: Paclitaxel · Drug: Ramucirumab

Interventions

  • Carboplatin IV

    Also known as: Paraplatin

  • Paclitaxel IV

    Also known as: Abraxane, Taxol

  • Ramucirumab IV

    Also known as: Cyramza

06

What researchers measure

Primary outcomes

  1. To estimate overall response rate

    Overall response rate (ORR) as determined by RECIST criteria. Response will be defined by a complete response (CR) or partial response (PRO), confirmed or unconfirmed.

    Time frame: 3 years

Secondary outcomes

  1. Progression-free survival

    Progression-free survival (PFS) defined as the duration from the first study dose of study drug until progressive disease, death or last assessment contact whichever comes first.

    Time frame: From first dose of study drug until progressive disease, death or last assessment contact, whichever comes first, an average of 1-2 years

  2. Overall Survival

    Overall Survival (OS) is defined as the time from the first dose of study drug until death due to any cause or last observation or contact.

    Time frame: from the first dose of study drug until death, last observation or contact, an average of 1-2 years

  3. Safety Evaluations: number of Grade ≥ 3 as determined by CTCAE v 5.0

    Toxicity will be estimated by the number of Grade ≥ 3 as determined by CTCAE v 5.0.

    Time frame: Initiation through 30 days following the last administration of study treatment.

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Oct 2026, 74 months.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 74 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2020
First posted
Apr 2, 2020
StartActual
Aug 1, 2020
Primary completionActual
Oct 1, 2026was Sep 2026
CompletionEst.
Jun 1, 2027was Sep 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 6, 2026
Primary completion
Sep 30, 2026→Oct 1, 2026 (actual)
Nov 6, 2026
Study completion
Sep 30, 2026→Jun 1, 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 30, 2026→Oct 1, 2026 (now actual)
    Study completion Sep 30, 2026→Jun 1, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04332367
Responsible party
Sponsor
First posted
Apr 2, 2020
Start date
Aug 1, 2020
Primary completion
Oct 1, 2026
Completion
Jun 1, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Melina Marmarelis, MD
principal investigator · Abramson Cancer Center at Penn Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Ramucirumab

Start the discussion